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Background: Quick reversal of warfarin anticoagulation is important in life threatening bleeding. The aim of this
study is to improve the administration delay when using Prothrombin Complex Concentrate (PCC) for the emergent
reversal of warfarin anticoagulation in the emergency department.
Methods: An audit and feedback quality improvement project was conducted in three phases: a retrospective audit
phase, an analysis and feedback phase and prospective evaluation phase. The charts of all eligible patients in a single
Emergency Department (ED) in Québec, Canada, who received PCC since the introduction of this product in 2009 until
October 31, 2011, were retrospectively audited. The administration delay of PCC was calculated from the time of
prescription to the time of administration. With the data, we determined where improvements could be attained,
and jointly with all stakeholders in the ED and the blood bank, we created an action plan to ensure the timely
administration of PCC. The action plan was then implemented and a six-month prospective evaluation study was
conducted to determine any improvement.
Results: Seventy-seven charts were reviewed in the retrospective chart audit. The mean administration delay was
73.6 minutes (STD [34.1]) with a median of 70.0 minutes (25–75% IQR [45.0–95.0]). We found that this delay was
principally due to the following barriers: communication problems between the ED and the blood bank as well as
delivery inefficiencies. An action plan that involved a flowchart to remind all clinicians how to order PCC and a new
delivery method from the blood bank to the ED were developed. During the 6 months following the implementation
of our action plan, 39 patients received PCC and the mean administration time decreased to 33.2 minutes (STD [14.2])
(p < .0001) with a median of 30.0 minutes (25–75% IQR [24.3–38.8]).
Conclusion: By implementing an action plan comprising of a flowchart and a new delivery process, this audit and
feedback quality improvement project reduced the administration time of PCC by more than half. Future studies to
measure the impact of a similar audit and feedback process involving an action plan in other centers should be
conducted before this type of quality improvement process is implemented on wider scale.
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Anticoagulation with oral warfarin is a common treat-
ment for long-term prevention in cardiac, cerebral,
pulmonary or lower limb thromboembolic events [1-3].
The use of this therapeutic modality is strongly recom-
mended in the medical literature but its narrow thera-
peutic index and the bleeding risk associated with the
therapy are often matters of concern [3]. In the event
of major life-threatening bleeding, such as intracranial
haemorrhage, delaying the reversal of anticoagulation
increases mortality [4-6]. Thus, quick reversal of antic-
oagulation in these cases is mandatory.
Two blood products–fresh frozen plasma (FFP) and
the new prothrombin complex concentrate (PCC)–are
used in addition to vitamin K to reverse warfarin antic-
oagulation in emergent situations [3,7-14]. Several stud-
ies have recently shown the efficacy of PCC over FFP in
the treatment of major bleeding caused by warfarin
[8,9,14-18]. The delay between prescription of FFP and
subsequent reversal of warfarin anticoagulation can be
long and may take hours [19-22]. In contrast, PCC-
mediated reversal of anticoagulation is achieved in only
10 to 15 minutes after administration [23,24]. In optimal
setup, it can take around 20 minutes to prepare PCC
and administer the product [25]. However, total adminis-
tration times between 60 to 200 minutes are reported in
the literature [7,20,26,27]. Shortening the time it takes to
prepare and administer PCC is essential because con-
trolling active bleeding sooner could lead to better clin-
ical outcomes [4-6,28,29].
In clinical practice, strong quality improvement pro-
grams are important as new products are continuously
implemented. Audit and feedback is one such quality
improvement process that generally leads to small but
potentially important improvements in professional
practice [30]. Audit and feedback is widely used as a
strategy to improve professional practice either on its own
or as a component of multifaceted quality improvement
interventions [30]. Professional practice and performance
are audited and compared to standards published in
clinical practice guidelines and other medical litera-
tures. The results of the audit are then analyzed with
the aim to give feedback to healthcare professionals so
that they improve their performance. Providing feed-
back with the support of an action plan has been shown
to improve its impact [30]. However, more evidence is
needed about how to develop these action plans and to
assess their impact on the quality of care [30]. Thus, we
report our experience with the development of an
action plan used to support an audit and feedback qual-
ity improvement project conducted to improve the
administration of PCC for the reversal of warfarin in the
context of life-threatening bleeding. The specific objec-
tives of this quality improvement project were to analysethe use of PCC in our emergency department (ED); to de-
velop an action plan to improve the administration delay
of PCC in our center; and to prospectively evaluate the
implementation of this action plan.
Methods
Study setting
This study was conducted at the CSSS Alphonse-
Desjardins (CSSS AD) as a three-part study. The CSSS
AD is a university-affiliated Level 2 trauma center that
receives a volume of sixty-five thousand visits per year.
Since PCC is a blood product, the blood bank stocks
and manages its use. Of the two PCC products available
in Canada (Octaplex®, Octapharma Canada [10] and
Beriplex®, CSL Behring Canada [11]), Octaplex® was the
one available at our center over the time of this study.
PCC is provided in a powder format kept in vials at
room temperature. When needed, PCC is reconstituted
with sterile water in a 6-step procedure [25]. PCC
administration requires no previous blood typing or
cross-matching [25]. When PCC were first introduced
at our institution in November 2009, a protocol for the
prescription (indications, doses, contraindications) of
PCC for emergency physicians was initially proposed by
our blood bank haematologist and then approved at the
transfusion medicine committee formed by an emer-
gency physician, ward physicians, the blood bank safety
officer and the blood bank haematologist [31]. When-
ever the PCC protocol was ordered by an emergency
physician, a written prescription was sent to the blood
bank by an ED nurse. A blood bank technician then
reconstituted the PCC after which an orderly was asked
to deliver the product to the ED where a nurse then
administered it. PCC is administered as an infusion at
1 cc per minute for 5 minutes then 2–3 cc per minute,
with a general starting dose of 2 vials and a total infusion
time of approximately 15 minutes for 2 vials (Octaplex®)
[25]. For patients over 90 kg, a higher dose was indicated
(maximum of 6 vials) [10,11,32].
Conceptual framework
To help guide the development of our quality improve-
ment project, we used the Ottawa Model of Research
Use framework (OMRU) (Figure 1) [33,34].
This framework employs a 6-step method to guide
the implementation of any evidence-based innovation.
The first step involves setting the stage by identifying all
the important stakeholders. Second, the innovation must
then be specified with its implementation implications.
Third, the OMRU calls for the conduct of an audit and
feedback process to identify the current knowledge im-
plementation gaps. Fourth, the OMRU proposes to se-
lect and implement knowledge translation strategies and
then, as a fifth step, to monitor the adherence to these
Figure 1 OMRU applied to our quality improvement project. OMRU: Ottawa Model of Research Use, ED: Emergency Department, PCC:
Prothrombine Complex Concentrate. Adapted from Logan and Graham: Toward a Comprehensive Interdisciplinary Model of Health Care Research
Use. Science Communication, December 1998 20:229 (with permission).
Table 1 Data collection tool
#
Age: Gender: Bleeding:
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work, it is suggested to measure the clinical impact of
implementing the knowledge innovation. In our project,
the important stakeholders were the blood bank tech-
nologists, the blood bank haematologist and the emer-
gency physicians, nurses and orderlies. Our innovation
was the evidence about increased mortality associated
with longer warfarin reversal and the need to decrease
time delays.
Phase 1: structured retrospective chart audit
The charts of all ED patients having received PCC be-
tween November 2009 and October 2011 were consid-
ered for inclusion. These charts were identified using a list
of patients generated by the blood bank for all patients
having received a prescription for PCC. Two reviewers
assessed the inclusion of each chart and extracted the data
using a structured extraction tool developed by the main
author (Table 1).
A chart was included only if the prescription of PCC
was for the reversal of major bleeding in an ED patientanticoagulated with warfarin. Charts were excluded if
the product was not administered in the ED, if no pre-
scription time or end of infusion time were written in
the chart or if the administration was cancelled. The
following data was retrieved from the included charts:
age, gender, time of prescription, start time of the recon-
stitution process, and end time of PCC infusion. We
calculated the administration delay as the difference
between the time the physician prescribed the blood
product and the time at the end of the infusion, as noted
by the nurse administering the PCC. A pre and post
reconstitution time delay was calculated. The pre
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the prescription time and the start of reconstitution of
the product, as noted in the medical chart by the blood
bank technician. The post reconstitution time delay
was considered as the difference between the reconsti-
tution starting time and the end of the infusion. We
used simple descriptive statistics to present the demo-
graphic information (age, gender) of the included
population and the means and medians for the differ-
ent time delays measured.
This chart audit was approved by the Head of the ED
who is responsible for our hospital’s quality improve-
ment program managed by the Council of Physicians,
Dentists & Pharmacists of the establishment (Québec,
LSSSS, sec. 190). Under this jurisdiction, no approval
from the institution’s ethics review committee is needed
to perform such chart audits and after reviewing our full
protocol, the ethics review committee (Comité d’éthique
de la recherche du Centre de santé et services sociaux
Alphonse-Desjardins (CER CSSS AD)) decided that our
study was exempt from formal ethical approval.
Phase 2: Identification of the barriers causing unwarranted
time delay, development of an action plan to address these
barriers and implementation of this action plan
After the completion of phase 1, the data was further
analysed by the authors. The total administration time
delay was broken down into its different components
in order to identify the main sources of delay. Results
of the chart audit were presented to all involved stake-
holders. Through open discussion and group deliber-
ation between authors and stakeholders, barriers to
delivering PCC in a timely manner were identified. A
comprehensive description of the current situation at
our institution (i.e. results of the chart audit, our
analysis of the causes for the different time delays, the
barriers to timely PCC administration and the solutions
proposed) was presented to the ED staff and to the
transfusion committee for feedback. After this feedback
was delivered, our research team and the stakeholders
involved in this project jointly produced an action plan
containing the strategies that were selected to improve
PCC administration time delays and to offer solutions
to the identified barriers.
Following the action plan development, the implemen-
tation was done in partnership with the blood bank, ED
physicians and the nursing staff. A description of the
important new steps in our developed action plan was
also presented to all these stakeholders. This presenta-
tion included a 10 minutes in-service training session
about the action plan. It was given to all concerned ED
and blood bank personnel before its implementation.
These training sessions were held by the transfusion safety
officer and the emergency nurse educator. Moreover, thesetraining sessions were financed by the institution. Finally,
the action plan was also presented to all emergency physi-
cians during a departmental meeting.
Phase 3: Prospective evaluation of the developed action
plan
Starting on June 1, 2012, all new cases of PCC prescrip-
tion in the ED were subjected to the changes proposed
by our action plan. Using the same data collection
methods used in phase 1, data was collected for a six-
month period between June 2012 and November 2012.
Once the action plan was implemented, we prospectively
collected data concerning administration delays in all
cases of PCC administration in the emergency depart-
ment. The transfusion safety officer collected the data
immediately after each case. As in phase 1, patients were
excluded if the product was not administered in the ED,
if no time was written in the chart, or if the prescription
was cancelled before administration. We collected data
using the same structured data extraction tool employed
in phase 1 (Table 1). However, we added ‘conformity with
the new procedures’ proposed by our action plan as a
new variable to extract. Non-conformity was considered
if clinicians failed to perform any of the steps in our
action plan. The reasons for non-conformity were
noted, but patients were not excluded from the analysis.
Similar to phase 1, we used simple descriptive statistics
to present the demographic information of our sample
(age, gender). We also calculated the mean and median
administration delays. We used the same time delay
definitions as phase 1. However, for this phase, we also
conducted a comparative analysis between the retro-
spective cohort (before the action plan) and prospective
cohort (after the implementation of the action plan) to
assess the impact of our action plan.
Statistical analyses
All the descriptive statistical analyses were performed
with Excel 2007 (Microsoft Corporation, Redmond, WA)
and the comparative statistical testing (Mann-Whitney
U test) was conducted with a free online calculator
(http://www.vassarstats.net/utest.html).
Results
Phase 1: structured retrospective chart audit
In all, 97 adult patients were ordered to receive PCC be-
tween 2009 and 2011. However, the charts of twenty of
these patients were excluded for the following reasons
(Figure 2): 1) not an emergency room prescription
(n = 16); 2) no administration time information charted
(n = 3); and 3) cancelled prescription (n = 1).
Thus, our retrospective audit was conducted with 77
charts. Simple demographic information on included
patients is reported in Table 2.
Figure 2 Patients flowchart.
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(STD [34.1]) with a median of 70 minutes (25–75% IQR
[55.0–95.0]) (Table 3).
A large variation in delay measures was found between
the cases (Figure 3). Only 36 charts had blood bank
reconstitution starting times noted in the chart. With
the available information in these 36 charts, the median
pre reconstitution time was 25.5 minutes (25–75% IQR
[12.8–34.5]). The median post reconstitution time was
43.5 minutes (25–75% IQR [31.0–60.0]).
Phase 2: Identification of the barriers causing unwarranted
time delays, development of an action plan to address
these barriers and implementation of the action plan
The main barriers identified in phase 2 were the ineffi-
cient communication processes between the ED and the
blood bank at the time of prescription, at the time of re-
constitution and at the time of delivery of the reconsti-
tuted product from the blood bank to the ED. Several
possible solutions to reduce the different time delays
were debated (e.g. modifying the administration protocol
and changing the site of reconstitution from the blood
bank to the ED). A decision was then taken by the trans-
fusion committee in partnership with the ED to review
how PCC were prepared and delivered to the ED. This
analysis of the delays and barriers resulted in the devel-
opment of our action plan. The action plan proposedTable 2 Demographic information
Phase 1




Number of patients 39
Age (Y) 75.8
Male sex 55%new procedures to reduce time delays caused by com-
munication, reconstitution and delivery problems.
During the development of our action plan, it was
decided to maintain the responsibility of reconstituting
PCC by blood bank technologists and not to transfer
this task to ED nurses in order to maintain a central
expertise for the whole hospital. In summary, our
action plan involved these two following elements: a
visual flowchart to remind all clinicians about the pro-
cedure to follow to order PCC from the blood bank
(Figure 4) and a new delivery method to transport the
ready-to-administer product from the blood bank to
the ED.
The decision to ask ED physicians to call the blood
bank directly rather than writing down an order and
sending it to the blood bank was a major change. The
visual flowchart was developed to inform and remind
prescribing physicians of this change. It was also decided
that ED physicians would be asked to advise the bedside
nurse to assign an orderly to retrieve the prepared prod-
uct immediately from the blood bank. Once the product
was retrieved, a nurse had to administer it at once.
Phase 3: Prospective evaluation of the newly developed
action plan
We prospectively collected information from 44 charts
for six months. Five cases were finally excluded because
no time information was recorded in the charts (n = 3),
or PCC were never administered because the original
order was cancelled (n = 2) (Figure 2). Thus, we analysed
a total of 39 cases of PCC administration. Demographic
and baseline information of these cases are found in
Table 2. As in phase 1, all patients received Octaplex®.
The mean administration delay was 33.2 minutes (STD
[14.2]) and the median time was 30 minutes (25–75%
IQR [24.25–38.75]). All of the new procedures proposed
by the action plan (illustrated in the flowchart - Figure 4)
were respected in 82% (n = 32) of cases analysed. The
mean administration delay for these 32 cases was
Table 3 Results
Time Phase 1 Phase 3 P value
Mean administration time (min) [STD] 73.6 [34.1] 33.2 [14.2] <.0001
Median administration time (min) [25–75% IQR] 70.0 [55.0–95.0] 30.0 [24.3–38.8]
Pre reconstitution median time (min) [25–75% IQR] 25.5 [12.8–34.5] xxx
Post reconstitution median time (min) [25–75% IQR] 43.5 [31.0–60.0] xxx
Time Phase 3 conform (82%) Phase 3 Non-conform (18%) P value
Mean administration time (min) [STD] 28 [7.8] 56.9 [12.8] 0.0002
Median administration time (min) [25–75% IQR] 28.0 [24.0–33.5] 58.0 [56.5–65.0]
Pre reconstitution median time (min) [25–75% IQR] 0 [0–0] xxx
Post reconstitution median time (min) [25–75% IQR] 28.0 [24.0–33.5] xxx
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and post action plan time delays, the administration delay
decreased from 73.6 minutes in phase 1 to 33.2 minutes in
phase 3 (p < .0001). There was less variation in delay mea-
surements in our prospective phase 3 cohort compared to
our retrospective phase 1 cohort (Figures 3 and 5).
After reviewing the seven cases with the highest time
delays in the prospective cohort, we noticed that all of
them failed to conform to the procedures proposed in
our action plan. Reasons for non-conformity included
the physician not calling the blood bank (n = 2), nurses
not sending an orderly to retrieve the product (n = 4)
and nurses not administering the product immediately on
reception (n = 1). The time delays for charts identified as
not conform were longer than for the charts that were













Figure 3 Delay between prescription and administration of PCC – Pha56.9 vs. 28.0 minutes (p = .0002)) (Table 3). For the 32
cases that respected the newly implemented procedures,
the median pre reconstitution time was 0 minute (25–75%
IQR [0–0]) and the median post reconstitution time was
28.0 minutes (25–75% IQR [24.0–33.5]).
Discussion
We performed an audit and feedback quality improve-
ment project supplemented with an action plan to im-
prove the administration delays of PCC in our center.
Our chart audit found that our administration delays
were high and could be improved. With the help of the
important stakeholders, we developed our action plan to
address the barriers we identified in administering PCC
quickly and safely. These barriers concerned mostly




Figure 4 Flowchart for the emergent administration of prothrombin complex concentrate (PCC) in the emergency department. The
goal of this chart is to reduce the delay to a minimum between the prescription and the administration of PCCs. We hope to achieve an optimal
reversal of warfarin anticoagulation in patients with major bleeding.
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blood bank. Our action plan involved providing under-
standing and training to all concerned personnel.
After implementing our action plan, we observed a
significant decrease in the administration time delays. By
comparing the pre and post reconstitution time delays
for both our cohorts, we were able to confirm that our
quality improvement project had a positive impact. One
of the major issues we identified in phase 1 and 2 was
the long pre reconstitution time delay that we believed
was due to a communication breakdown between the
ED and the blood bank. Part of our action plan was to
ask ED physicians to call the blood bank directly to
order PCCs instead of simply writing an order. After
implementing this change, there was a reduction in this
time delay.
As for the reconstitution of the product, it was de-
cided to maintain the responsibility of preparing PCC by
blood bank technologists as opposed to having EDnurses prepare the product in the ED, because PCC are
blood products and reconstitution involves a few critical
steps that benefit from having the expertise of a blood
bank technician [25]. Moreover, concentrating this ex-
pertise in one place reduces the risk of errors and opti-
mises reconstitution times for the whole hospital. We
also believe that changing the way orderlies retrieved the
prepared product improved the total administration
delay. Our action plan involved immediately assigning
an orderly to retrieve the product from the blood bank,
even before it was ready, to minimise delivery time.
We also found that charts that were not conform to
the action plan increased the administration delay.
Without these events, we would have gained five more
minutes in mean delay reduction (28.0 vs. 33.2 minutes).
Since the goal of a quality improvement project is to re-
duce deviant practices, we believe that by providing
regular in-house training, using a visual flowchart and




















Figure 5 Delay between prescription and administration of PCC - Phase 3.
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municates information visually and quickly. It requires
little training to understand. Simple methods such as
a flowchart can greatly improve administration, but
adherence may be hindered by a variety of barriers [35].
In addition to the flowchart, all concerned personnel
received a short in-service training. With this quality
improvement project involving audit and feedback sup-
plemented by an action plan, we improved our hospital’s
performance with regards to PCC administration times in
emergent situations. This reduction in PCC administra-
tion time accelerated the reversal of anticoagulation and
helped clinicians stabilize their patients faster.
Even though our administration delays in phase 1 were
comparable to those found in the literature before our
feedback process [7,20,26,27], they were much higher
than the optimal time [25]. However, after our audit and
feedback process and the implementation of our action
plan, our administration time decreased to 33 minutes
which is close to the shortest administration delay possible.
This study has some limitations. We did not compare
our intervention to another control intervention to serve
as a point of reference. Thus, our positive findings could
be influenced by a Hawthorne effect [36]. Moreover, we
did not blind participants or outcome assessors. Thus,
well-intentioned personnel seeking to improve their own
performances could have charted better times of product
prescription or end of administration times in phase 3.
However, the fact that some of our measurements were
charted by two different individuals (e.g. prescription
times for PCC were charted both by ordering physiciansand by the blood bank technologist) and that they did
not differ makes this bias less likely. Also, our project
did not verify if each prescription of PCC was written
for a recognized indication or evaluate the appropriate-
ness of PCC prescriptions. However, in order to minim-
ise inappropriate usage and prior to phase 3, we updated
our protocol (revised by our blood bank haematologist
and then approved at the transfusion medicine commit-
tee) for PCC prescription to include a complete list of
appropriate indications, the correct dosing regimen and
the important contraindications [31]. We also reviewed
this protocol with the emergency physicians during the
presentation of our action plan.
Our research did not look at some of the delays that may
occur before or after the prescription of PCC. Time delays
caused by obtaining CT scans before PCC administration
in case of intracranial haemorrhage can significantly slow
down the process of reversing anticoagulation in this sub-
group of patients [37] and reduce any gains due to our
protocol. Time needed to obtain an INR may also delay the
administration of PCC, given that the dose of PCC is
dependent on the INR [38]. Rapid INR testing at the ED or
PCC dosing independent from the INR may avoid this
delay in emergent situations [31,38,39]. Lastly, administra-
tion time may vary between 15 to 30 minutes depending of
the volume given, which depends on the weight, the INR,
and the maximum infusion time specified by the manufac-
turer [25,32]. It has been shown in some studies that infu-
sion time around 5 minutes are safe without increasing the
thrombotic risk therefore leading to further reduction of
the time needed to achieve anticoagulation reversal [38,40].
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our quality improvement project describes how we
developed a novel action plan to help implement the
changes needed to improve PCC administration times.
Audit and feedback are more effective when baseline
performance is low, when the source is a supervisor
or colleague, if it is provided more than once, if it is
delivered in both verbal and written formats, and
when it includes both explicit targets and an action
plan [30]. Our study confirms that audit and feedback
supplemented with a tailored action plan improved
patient care by cutting the PCC administration delay
by more than half in anticoagulated patients with
warfarin presenting with major bleeding. Concerning
our use of the OMRU, we also believe that it was
one of the key elements to help us understand how
our action plan helped us reduce the administration
time of PCC in our institution. The OMRU helped us
conceptualise how our action plan needed to be im-
plemented. It helped us identify and involve the im-
portant stakeholders to develop an action plan that
they would adopt. It also helped us identify the im-
plementation barriers to our action plan and select the ap-
propriate strategies adapted to our milieu to address these
barriers. Finally, it helped us to monitor the adoption of
our action plan and measure its impact.
Even though our quality improvement project was
able to cut administration times, a local audit will be
held each year at our institution to assess if our positive
results are maintained. The impact of our quality im-
provement process performed in other centers and set-
tings should also be studied to confirm our results.
Although, it seems reasonable to believe that reducing
PCC administration time could improve patient out-
comes by controlling bleeding faster, future studies
must also be conducted to measure the impact of this
reduction on outcomes such as mortality and appropri-
ate use of PCC.
Conclusion
Warfarin anticoagulation reversal in life-threatening
bleeding situations must be quick and performed
without delay. New products are available but an
efficient administration process is warranted in the
emergency department. An audit and feedback pro-
cess involving the development and use of an action
plan summarized on a flowchart reduced the admin-
istration time of PCC by more than half. This process
optimised the administration of PCC in emergent situa-
tions and reduced anticoagulation reversal delays in our
ED. Although further improvements to reduce overall
treatment time could make our action plan even more
useful, an assessment of its impact on patient outcomes
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